Secondary Prevention of Stroke: The role of the General Practitioner
Poster Apr 23, 2013
The increased risk of ischaemic events following a stroke, and the associated morbidity and mortality, makes secondary prevention an important therapeutic goal. Nevertheless, for reasons relating to both physicians and patients, a well documented gap remains between evidence and clinical practice in many aspects of cardiovascular disease.
Reducing the burden of recurrent stroke clearly relies not only on an increasing understanding of the aetiologial factors that influence the development of stroke, but also on the services of primary care physicians such as lifestyle modifications, pharmacological treatment and referral for consideration of surgery.
Assessment of secondary prevention and the discrepancy between evidence and practice is difficult due to the variations between clinical studies, for example in different target populations, length of follow up, drop out rates and outcomes. It is similarly challenging to relate the results of these clinical trials to individual patients, each with numerous risk factors of varying significance.
These results support the use of hSC-CM and MEA technology for preclinical assessment of proarrhythmic risk within the proposed CiPA paradigm, and, more generally, demonstrate that automation of the CM-MEA assay can achieve high reliability and throughput for cardiac risk assessment in vitro.READ MORE